10th Pharmacovigilance Conference

From Verify.Wiki
Jump to: navigation, search
Wizard photo 10th Pharmacovigilance Conference 1.JPG
10th Pharmacovigilance Conference
Date 2017-01-25
Place Radisson Blu Portman hotel, 22 Portman Square, London W1H 7BG, UK

"The 10th Pharmacovigilance conference organized by Medicines for Europe[1]  is a unique event where key stakeholders gather with the aim of promoting patient safety and undertaking, to continue work towards a more efficient pharmacovigilance system. In the spirit of constructive cooperation, this event brings together representatives from the industry and regulators as well as healthcare professionals and patient organisations. It took place on January 25th of 2017 at the Radisson Blu Portman Hotel, 22 Portman Square, London W1H 7BG. UK."

"Industries provide sustainable access to high quality medicines for all European patients, for generic, biosimilar and value added medicines. Every single day, industries increase access to the best standard of care in all therapeutic areas.Industries provide sustainable access to high quality medicines for all European patients, for generic, biosimilar and value added medicines. Every single day, industries increase access to the best standard of care in all therapeutic areas"....

"Between 2005 and 2015, for the same budget, generic competition allowed twice as many patients access to medicines for key therapeutic areas such as diabetes, depression, epilepsy, cardiovascular disease, hypertension, asthma/COPD or gastro-intestinal disease.Between 2005 and 2015, for the same budget, generic competition allowed twice as many patients access to medicines for key therapeutic areas such as diabetes, depression, epilepsy, cardiovascular disease, hypertension, asthma/COPD or gastro-intestinal disease.."

"Biosimilar medicines have also increased access to treatment with complex biological medicines. For instance, the introduction of biosimilar filgrastim, used to treat the consequences of chemotherapy, increased patient access by 44% across Europe. Not only could more patients get access to this treatment but physicians were also able to use the medicine earlier in the treatment cycle, to the benefit of the patient."..

About the Conference

Conference Series is organizing splendorous Pharmaceutical conferences welcomes you to attend the 12th International Conference and Exhibition on Pharmacovigilance & Drug Safety to be held during July 04-05, 2019 in Valencia, Spain. It focuses on the advancements in Pharmacovigilance, Risk Management, and Drug Safety.

The field of Pharmacovigilance is growing rapidly and its development is making tremendous impacts in medical sciences and pharmaceuticals. 12th International Conference and Exhibition on Pharmacovigilance & Drug Safety  emphasizes on how the importance and significance can be gauged by the fact that it has made huge advancements over the course of time and is continuing to influence various sectors. 

Why to attend???

With members from around the world focused on learning about Pharmacovigilance and its advances; this is your best opportunity to reach the largest assemblage of participants from the Pharmacovigilance community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive named recognition at this 2-days event. World-Renowned Speakers, the most recent techniques, developments, and the newest updates in Pharmacovigilance are Hallmarks of this Conference.

Target Audience:

  • Pharmacovigilance Students, Scientists
  • Pharmacovigilance Researchers
  • Pharmacovigilance Faculty
  • Medical Colleges
  • Pharmacovigilance Associations and Societies
  • Business Entrepreneurs
  • Training Institutes
  • Software Developing Companies
  • Manufacturing Medical Devices Companies
  • Data Management Companies

Sessions/Tracks

Track 1: Pre-Clinical and Clinical Trials

Clinical trials allow the drug to be tested for safety by different ethnic population. Due to the higher medical needs and increasing disease prevalence, developing countries are becoming a hub for clinical trial execution. The clinical trials market has been estimated to reach USD 14.2 billion in 2016 and is projected to reach around USD 22 billion by the year 2021, and the annual growth rate of (7.5%). There are additionally numerous clinical trials started by scholarly clinical scientists. Whether started by industry or by scholastic clinical examiners and research is frequently performed in national, European and overall consortia, which can be expansive ones. Clinical research brings up moral and security issues. Clinical research is exceedingly controlled. To encourage and coordinated efforts crosswise over fringes.

Related Conferences:

Pharmacovigilance Conferences | Global Pharmacovigilance Conferences | Clinical Trials Conference | Drug Safety Conference | Clinical Case Reports Conferences | Case reports Conference | Clinical development Conferences | Drug Research Conferences | Good clinical practice Conferences | Good pharmacovigilance practices Conferences | Pharmacovigilance and Risk Management Conferences | Risk Management Conferences | Regulatory Affairs Conferences .

19th  World Congress on Pharmaceutical Sciences & Innovations in Pharma Industry February 25- 26, 2019 Berlin, Germany; 4th Conference on Antibiotics Conference; June 14-15, 2019, Barcelona, Spain; 13th European Pharma Conferences May 07-09, 2019 at Frankfurt, Germany; 5th International Conference on Advanced Clinical Research and Clinical Trials, September 10-11, 2018 at Zurich, Switzerland; 12th  European Biosimilars Congress, April 15-16, 2019 Berlin, Germany; 21st Annual European Pharma Congress May 20-21, 2019 Zurich, Switzerland;  4th International Conference on Drug Discovery and Advanced Drug Delivery Systems & Technologies, October 18-19, 2018 at Warsaw, Poland; 18th Annual Pharmaceutical Chemical Analysis Congress, November 05-06, 2018 at Madrid, Spain; 9th Global Experts Meeting on Neuropharmacology, November 15-16, 2018 at Frankfurt, Germany; 3rd International Conference on Generics Drugs and Biosimilars, November 15-17, 2018 at Frankfurt, Germany; Exhibition, December 02-06 2018 at Anaheim, USA; 78th Congress of Pharmacy and Pharmaceutical Sciences, September 02-06, 2018 at Glassglow, UK; 14th Nanomedicine and Pharmaceutical Nanotechnology Conferences, April 09-11, 2019, London, UK.

Related Journals:

Journal of Pharmacovigilance | International Journal of Pharmacovigilance | The International Journal of Risk & Safety in Medicine | Pharmacovigilance | Pharmacoepidemiology | Trials Journal | Clinical Research Journals | Journal of Clinical Trials | International Journal of Clinical Trials | American Journal of Clinical Trials | International Journal of Medical | Clinical Research, Journal of Pharmacology | Clinical Research | Asia Pacific Journal of Clinical Trials | Advances in Pharmacoepidemiology | Drug Safety | Drug Safety Journal | International Journal of Drug Safety | Drug Discovery | Journal of Drug Safety | Journal of Clinical Case Reports, Indian Journal of Case Reports | American Journal of Case Reports.

Related Associations or Societies:

Societies in USA: International Society of Pharmacovigilance | Drug Safety & Pharmacovigilance | Association of Clinical Research Professionals (ACRP) | American Association of Pharmaceutical Scientists | Association of British Pharmaceutical Industry | the Society of Clinical Research Associates (SOCRA) | Society for Clinical Trials (SCT) | Canadian Association of Professionals in Regulatory Affairs | Clinical Research Society (CRS)

Societies in Europe:  European Association for Clinical Pharmacology (EACPT) | International Society of Pharmacovigilance (ISOP) | European Medicines Agency, Pharmaceutical Information and Pharmacovigilance Association (PIPA) | Association of CROs Czech Republic (ACRO-CZ) | European Clinical Research Infrastructures Network (ECRIN) | European Society for Clinical Investigation (ESCI).

Societies in Asia and Pacific: Society of Pharmacovigilance, International Society of Pharmacovigilance: (ISOP) | Indian Society for Clinical Organization Research (ISCR) | Indian Society for Clinical Research | Clinical Trials Society | Society for Clinical Trials Association of Clinical Research | The Society of Clinical Research Associates | Association of Clinical Research Organization | Clinical Research Society | Indian Council of Medical Research (ICMR) | Japan CRO Association (JCROA) | Pan-Asian Clinical Research Association (PACRA) | Central Society for Clinical and Translational Research (CSCTR)

Track 2: Adverse Drug Reactions

Adverse drug reactions can be considered a form of toxicity or enhanced drug effects that occur during appropriate use (eg, when drug metabolism is temporarily inhibited by a disorder or another drug). In the US, 3 to 7% of all hospitalizations are due to adverse drug reactions. ADRs occur during 10 to 20% of hospitalizations; about 10 to 20% of these ADRs are severe. Incidence of death due to ADRs is unknown; suggested rates of 0.5 to 0.9% may be falsely high because many of the patients included had serious and complex disorders. Incidence and severity of adverse drug reactions vary by patient characteristics (eg, age, sex, ethnicity, coexisting disorders, genetic or geographic factors) and by drug factors (eg, type of drug, administration route, treatment duration, dosage, and bioavailability). Incidence is higher with advanced age and polypharmacy.

Related Conferences:

Case Study Conferences | Pharmacovigilance and Drug Safety Meetings | Adverse Drug Reactions Conferences | Pharmacovigilance Practice Conferences | Pharmacy Practices Conferences | Risk Management and Pharmacovigilance Conferences | Challenges in Clinical Trials Conferences | Pharmacology and Pharmacovigilance Conferences | Clinical Trials and Drug Safety Conferences | Global Clinical Trials Conferences

4th Conference on Antibiotics Conference; June 14-15, 2019, Barcelona, Spain; 13th European Pharma Conferences May 07-09, 2019 at Frankfurt, Germany; 5th International Conference on Advanced Clinical Research and Clinical Trials, September 10-11, 2018 at Zurich, Switzerland; 12th  European Biosimilars Congress, April 15-16, 2019 Berlin, Germany; 21st Annual European Pharma Congress May 20-21, 2019 Zurich, Switzerland;  4th International Conference on Drug Discovery and Advanced Drug Delivery Systems & Technologies, October 18-19, 2018 at Warsaw, Poland; 18th Annual Pharmaceutical Chemical Analysis Congress, November 05-06, 2018 at Madrid, Spain; 19th  World Congress on Pharmaceutical Sciences & Innovations in Pharma Industry February 25- 26, 2019 Berlin, Germany; 9th Global Experts Meeting on Neuropharmacology, November 15-16, 2018 at Frankfurt, Germany; 3rd International Conference on Generics Drugs and Biosimilars, November 15-17, 2018 at Frankfurt, Germany; Exhibition, December 02-06 2018 at Anaheim, USA; 78th Congress of Pharmacy and Pharmaceutical Sciences, September 02-06, 2018 at Glasgow, UK; 14th Nanomedicine and Pharmaceutical Nanotechnology Conferences, April 09-11, 2019, London, UK.

Photos

Top Videos

https://www.youtube.com/embed/rFoJvdc7v0U

Topics

Consists of morning sessions which reflect on achievements so far and focus on the milestones ahead and afternoon brainstorming sessions, which stimulate a lively engaging debate incorporating all perspectives.[2]

Session 1: Pharmacovigilance legislation: what are the next steps? Reflections from the Commission, European Medicines Agency and the Industry.

  • Chair: June Raine, PRAC Chair, Director of Vigilance and Risk Management of Medicines, Medicines and Healthcare products Regulatory Agency (MHRA), UK,
  • The 3-year Commission report and Impact assessment, led by the EMA - Helen Lee, DG SANTE, European Commission
  • Scanning the horizon 2017+: what are the milestones ahead of us? - Georgy Genov, Acting Head of Pharmacovigilance and Epidemiology Department, European Medicines Agency (EMA)
  • Industry’s role in patients’ safety and 2017 priorities - Wendy Huisman, Medicines for Europe PhV Working Group Chair, EU QPPV, TEVA
  • Questions and answers:
    • Social media and technology supporting patient safety: opportunities and pitfalls - David J. Lewis, Global Head of Pharmacovigilance, Novartis Pharma AG
  • Panel discussion with Phil Tregunno, Signal Management Unit Manager, Medicines & Healthcare products Regulatory Agency (MHRA), session speakers and interaction with the floor.

Session 2: Enhanced EudraVigilance & Signal Detection – how to prepare for the upcoming milestones? Reflections of the regulators and the industry perspective.

  • Chair: Uwe Gudat, Head of Safety, Biosimilars, Merck Biosimilars
  • Overview of the new process for Signal Detection and Management - Georgy Genov, Acting Head of Pharmacovigilance and Epidemiology Department, European Medicines Agency (EMA)
  • EudraVigilance stakeholder change management Plan- How to prepare for the changes - Sabine Brosch, Principal Scientific Administrator, European Medicines Agency (EMA)
  • Industry Readiness for the New EudraVigilance -How can companies ensure smooth implementation? – Uwe Gudat, Head of Safety, Biosimilars, Merck Biosimilars.

Session 3: Mini Workshops: how to improve pharmacovigilance activities?

  • Chair: Sabine Straus, Dutch representative of the PRAC, Head of Pharmacovigilance, Medicines Evaluation Board (MEB)
  • Educational material – is there a more efficient way to educate? - Wendy Huisman, Medicines for Europe PhV Working Group Chair, EU QPPV, TEVA
  • Medical literature monitoring – service improvements after one year implementation - John Barber, QPPV and Director, Head of Pharmacovigilance, European Operations, Dr. Reddy’s Invited: Tom Paternoster-Howe, European Medicines Agency (EMA)
  • Pharmacovigilance inspections and compliance – is there a more efficient way when companies are auditing each other? - Julia Appelskog, QPPV, Head of Pharmacovigilance, Bluefish Pharmaceuticals.
  • Signal detection – what changes to implement and how? - Nicole Lang, Senior Director, PhV TA Group Leader, Biologics, Respiratory & IM, Global Patient Safety & Pharmacovigilance, TEVA
  • Topic 5: Pharmacovigilance of biologicals – implementation of GVP P.II recommendations - Michael Forstner, Managing Director, Mesama-Consulting, Switzerland

Brief summary of the workshops - Sabine Straus, Dutch representative of the PRAC, Head of Pharmacovigilance, Medicines Evaluation Board (MEB), NL and topic leads

Chairpersons And Speakers

Adrian van den Hoven:

Director General, Medicines for Europe

June Raine, Dr:

PRAC Chair, Director of Vigilance and Risk Management of Medicines, Medicines and Healthcare products Regulatory Agency (MHRA), UK


Helen Lee:

Administrator, DG SANTE European Commission

Wendy Huisman

Medicines for Europe PhV Global Head of Working Group Chair, EU, Pharmacovigilance


David J. Lewis

OPPV, Teva Systems and Data Management, Novartis

Phil Tregunno

Signal Management & Quality Standards Unit Manager, Medicines & Healthcare products Regulatory Agency (MHRA)

Georgy Genov

Acting Head of Pharmacovigilance and Epidemiology Department, European Medicines Agency (EMA)

Uwe Gudat

Head of Safety Biosimilars, Merck Biosimilars

Sabine Brosch, Mpharm, RNDr Principal Scientific Administrator, Surveillance and Epidemiology Service, Pharmacovigilance and Epidemiology Department, European Medicines Agency (EMA)

Sabine Straus

Dutch Representative of the PRAC, Head of Pharmacovigilance, Medicines Evaluation Board (MEB)

Jamie Wilkinson, MSc, PGCert, MPharm (Hons), Dip HE, FRSPH

MRPharmS, Director of Professional Affairs, Pharmaceutical Group of the European Union (PGEU)

John Barber

QPPV and Director, Head of Pharmacovigilance, European Operations, Dr. Reddy's

Tom Paternoster-Howe

European Medicines Agency (EMA)

Julia Appelskog

QPPV and Head of Pharmacovigilance, Bluefish Pharmaceuticals

Joanna Harper

Expert GPVP Inspector, Medicines & Healthcare products Regulatory Agency (MHRA)

Nicole Lang

Senior Director, PhV TA Group Leader, Biologics, Respiratory & IM, Global Patient Safety & Pharmacovigilance, TEVA

Michael Forstner

Managing Director and Head Pharmacovigilance, Pharmacoepidemiology Practice, Mesama Consulting Switzerland

Barbara Claus

Hospital Pharmacist, Ghent University Hospital

Katarina Nedog

Safety & Regulatory Manager, Medicines for Europe

Top Quotes

Dr June Raine: "Massive penetration in benefit risk to proactive monitoring product life cycle helping to reach pro decision and involving HCP and patient on the safety and all of this in new era of openness and transparency."

Event Sponsors and Media Partners

  • GaBi - Generics and Biosimilars initiative
  • Generics-Bulletin.com
  • PharmaPhorum
  • PharSolution
  • QuintilesIMS [2]

References

  1. http://www.medicinesforeurope.com/
  2. 2.0 2.1 http://www.medicinesforeurope.com/events2017/PHV17_Programme.pdf

Verification history